Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment

Next Previous
X
Search
Trial Profile

Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
  • Focus Therapeutic Use
  • Acronyms PARCT

    • Most Recent Events

    • 21 Feb 2024 Status changed from active, no longer recruiting to discontinued.
    • 26 Aug 2022 This trial have been completed in Germany and Greece (Date of the global end of the trial : 22-Aug-2022), according to European Clinical Trials Database record.
    • 01 Oct 2021 Results (n=26; between 23rd October 2018 and 16th September 2019) assessing efficacy of atezolizumab in the treatment of stage IIb-IVB mycosis fungoides/Sezary syndrome patients relapsed/refractory after a previous systemic treatment, published in the European Journal of Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top